Navigation Links
InterMune Reports Preliminary Fourth Quarter 2011 Esbriet® (pirfenidone) Revenue and Other Recent Business Highlights
Date:1/5/2012

d range announced during InterMune's Third Quarter 2011 earnings call of $160 to $180 million.

Guidance for 2012 Expenses

The company provided its forward-looking financial guidance for operating expenses in 2012:

  • R&D expense: currently anticipated to be in a range of $95 to $115 million
  • SG&A expense: currently anticipated to be in a range of $120 to $145 million. 
  • Total Operating Expenses (R&D and SG&A): currently anticipated to be in a range of $215 to $260 million.


Conference Call and Webcast Details

InterMune will host a live webcast of a conference call today at 8:30 a.m. EST to discuss the Esbriet launch in Germany, the plans to launch Esbriet in other countries in the EU, the RECAP data and its updated operating expense guidance for 2011 and forward-looking operating expense guidance for 2012.  Interested investors and others may participate in the conference call by dialing 888-567-5125 (U.S.) or 706-643-9223 (international), conference ID# 40200495.  A replay of the webcast and teleconference will be available approximately three hours after the call.

To access the webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A telephonic replay will be available for 10 business days following the call and can be accessed by dialing 855-859-2056 (U.S.) or 404-537-3406 (international), and entering the conference ID# 40200495.   

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases.  In pulmonology, we are focused on
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. InterMune Appoints Angus C. Russell to Board of Directors
2. InterMune to Release Third Quarter Financial Results on November 3
3. InterMune Announces Launch of Esbriet® (pirfenidone) in Germany
4. InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
5. InterMune Receives European Union Approval for Esbriet® (pirfenidone)
6. InterMune Reports Fourth Quarter and Full Year 2010 Financial Results and Business Highlights
7. InterMune to Present at J.P. Morgan Healthcare Conference
8. InterMune Reports Third Quarter 2010 Financial Results
9. InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS)
10. InterMune to Release Second Quarter Financial Results on July 27
11. InterMune Announces Conference Call and Webcast to Discuss Outcome of FDA Advisory Committee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... 17, 2014 ... ) has announced the addition of ... American Automated External Defibrillators (AED) Market" ... http://photos.prnewswire.com/prnh/20130307/600769) ,The report North American Automated ... market of devices based upon following ...
(Date:10/17/2014)... , October 17, 2014 ... Pharmaceuticals Inc. (NASDAQ: ARNA ), NPS Pharmaceuticals ... XOMA ), Momenta Pharmaceuticals Inc. (NASDAQ: ... CPRX). Free research on these five companies can be ... markets on Thursday, October 16, 2014, ended on a ...
(Date:10/17/2014)... , Oct. 17, 2014  Talyst, a market leader ... LeadingAge Annual Meeting in Nashville, TN. ... the market leading solution for onsite, remote medication dispensing. ... care facilities to safely and securely dispense medication onsite, ... first dose, helps ensure that the correct medication gets ...
Breaking Medicine Technology:Micro Market Monitor : North American Automated External Defibrillators (AED) Market 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5Talyst Exhibits at LeadingAge Annual Meeting 2
... Feb. 21, 2012 ConvaTec, a world-leading developer and ... care, today announces that Ken Berger will assume the ... the ConvaTec Board of Directors. Berger joins ... last ten years, most recently as Senior Vice President ...
... Feb. 21, 2012  Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX ... overview at the Citi Global Healthcare Conference on February 27, ... New York City.   The live and archived ... of Events" in the Idenix Investor Center at ...
Cached Medicine Technology:ConvaTec Announces the Appointment of Ken Berger to the Position of CEO Effective March 6, 2012 2
(Date:10/20/2014)... (PRWEB) October 20, 2014 JZ Fitness, ... nutritional coaching, corporate wellness programming, authorship, international lecturing and ... excited to announce the release of the JZ Fitness ... many years of coaching thousands of individuals on nutrition, ... app that does not require calorie counting or cumbersome ...
(Date:10/20/2014)... 20, 2014 Principle Business Enterprises, a ... in manufacturing top-of-the-line absorbent products. The company has ... most popular brand, Tranquility® Premium Protection absorbent products. ... website, gave its packaging a new look, and is ... message to the public. , The new website, developed ...
(Date:10/20/2014)... 20, 2014 Myoderm ... Assistant Director of their CentralSource service. ... the innovative turnkey drug sourcing, distribution, and management ... over 12 years of industry experience, in both ... the peak of their international success to help ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Succeed is proud ... local companies who participated in the Every Body Walk! ... a public awareness project that encourages workers to be more ... Step 10,000 Program, which concluded at the end of September, ... of cities and metro areas. Participating companies gave their ...
(Date:10/20/2014)... 20, 2014 National Teen Driver Safety Week ... American Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ) is ... parents of teen drivers to talk to their teens and ... Motor vehicle crashes are the leading cause of death for ... in fatal crashes, and 859 (42%) of those teen drivers ...
Breaking Medicine News(10 mins):Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2
... Nearly one in three women who have breast cancer ... additional surgery after the tumor is evaluated by a pathologist. ... Cancer Center cuts that number drastically by having pathologists on-site ... immediately after they are removed. Meanwhile, the surgeon and patient ...
... News) -- Drug-free recovery housing and day treatment programs ... who have gone through detoxification will be able to ... abuse includes both the use of illegal drugs such ... such as OxyContin, Vicodin and Percocet. Opioid addicts ...
... alone, approximately 6 million people suffer from an irregular ... with age, it is predicted that 15.9,million Americans will ... of AF is stroke, but,a new device from Boston ... Atritech, now part of Boston Scientific, developed the WATCHMAN ...
... MONDAY, Feb. 27 (HealthDay News) -- Many people with stable ... work just as well, a new study suggests. The ... a clogged artery. As many as three-quarters of these operations ... professor of medicine at Stony Brook University Medical Center in ...
... A great deal has been learned in the ten years ... (WHI). Hormone therapy (HT) remains the most effective treatment available ... a growing body of evidence that formulation, route of administration, ... effects. It is essential to evaluate a personal ...
... the country tripled to nearly three per year between 1994 ... 15 years, according to an analysis of weather conditions and ... Georgia researchers. The scientists built a detailed database ... well as the height, weight and position for 58 football ...
Cached Medicine News:Health News:Fewer women need repeat breast cancer surgeries with new service at University of Michigan 2Health News:Drug-Free Housing Helps Heroin, Oxycontin Addicts Recover 2Health News:Stroke-preventing technology demonstrated in JoVE 2Health News:Stents No Better Than Medicine for Stable Heart Disease, Study Says 2Health News:Stents No Better Than Medicine for Stable Heart Disease, Study Says 3Health News:The North American Menopause Society (NAMS) reassures many women 2Health News:Deaths triple among football players, morning temperatures thought to play a role 2